Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled Trial

American Journal of Kidney Diseases

Volumn 51, Issue 5, 2008, Pages 724-731

  Szeto, Cheuk Chun ^a   Chow, Kai Ming ^a   Kwan, Bonnie Ching Ha ^a   Chung, Kwok Yi ^a   Leung, Chi Bon ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic kidney disease; proteinuria; renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE URINE LEVEL; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; SKIN PRURITUS; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; CALCITRIOL; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENAL AGENTS;

EID: 43049104680     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.12.038     Document Type: Article

References (25)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 245 (1987) 709-727
2. Li P.K.T., Ho K.K.L., Szeto C.C., Yu L.M., and Lai F.M. Prognostic indicators of IgA nephropathy in the Chinese-Clinical and pathological perspectives. Nephrol Dial Transplant 17 (2002) 64-69
3. Haas M. Histologic subclassification of IgA nephropathy: A clinico-pathologic study of 244 cases. Am J Kidney Dis 29 (1997) 829-842
4. Maschio G., Cagnoli L., Claroni F., et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9 (1994) 265-269
5. Russo D., Pisani A., Balletta M.M., et al. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33 (1999) 851-856
6. Perico N., Remuzzi A., Sangalli F., et al. The antiproteinuria effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9 (1998) 2308-2317
7. Li P.K., Leung C.B., Chow K.M., et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47 (2006) 751-760
8. Coppo R., Peruzzi L., Amore A., et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18 (2007) 1880-1888
9. Ruggenenti P., Perna A., Gherardi G., Benini R., and Remuzzi G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35 (2000) 1155-1165
10. Dillon J.J. Treating IgA nephropathy. J Am Soc Nephrol 12 (2001) 846-847
11. Pozzi C., Bolasco P.G., Fogazzi G.B., et al. Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet 353 (1999) 883-887
12. 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53 (1998) 1696-1705
13. To K.F., Choi P.C., Szeto C.C., et al. Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis 35 (2000) 392-400
14. Ma Y.C., Zuo L., Chen J.H., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) 2937-2944
15. Jones G., Strugnell S.A., and Deluca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 78 (1998) 1193-1232
16. Brown A.J. Vitamin D analogues. Am J Kidney Dis 32 suppl 2 (1998) S25-S39
17. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124 (1989) 2645-2647
18. Abe H., Iehara N., Utsunomiya K., Kita T., and Doi T. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-β type II receptor-mediated manner. J Biol Chem 274 (1999) 20874-20878
19. Makibayashi K., Tatematsu M., Hirata M., et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158 (2001) 1733-1741
20. Li Y., Spataro B.C., Yang J., Dai C., and Liu Y. 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 68 (2005) 1500-1510
21. 3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286 (2004) F526-F533
22. Hirata M., Makibayashi K., Katsumata K., et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17 (2002) 2132-2137
23. Agarwal R., Acharya M., Tian J., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68 (2005) 2823-2828
24. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., and Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 (2002) 229-238
25. Mizobuchi M., Morrissey J., Finch J.L., et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18 (2007) 1796-1806